TG Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade TG Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About TGTX
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib.
CEOMichael Sean Weiss
CEOMichael Sean Weiss
Employees338
Employees338
HeadquartersMorrisville, North Carolina
HeadquartersMorrisville, North Carolina
Founded1993
Founded1993
Employees338
Employees338
TGTX Key Statistics
Market cap6.36B
Market cap6.36B
Price-Earnings ratio164.18
Price-Earnings ratio164.18
Dividend yield—
Dividend yield—
Average volume1.62M
Average volume1.62M
High today$40.54
High today$40.54
Low today$39.41
Low today$39.41
Open price$40.00
Open price$40.00
Volume2.14M
Volume2.14M
52 Week high$46.48
52 Week high$46.48
52 Week low$15.16
52 Week low$15.16
TGTX News
Simply Wall St 1d
TG Therapeutics (NasdaqCM:TGTX) Stock Rises 13% In Last Monthsaw its share price rise by 13% last month. This period witnessed significant market fluctuations, such as the S&P 500 hitting 6,000 for the first time since Fe...
Analyst ratings
88%
of 8 ratingsBuy
87.5%
Hold
0%
Sell
12.5%
People also own
Based on the portfolios of people who own TGTX. This list is generated using Robinhood data, and it’s not a recommendation.